SCHEMBL226231

SCHEMBL226231

CCN(C)C(=O)CCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9613929 0.80
SCHEMBL31443083 0.80 ALDH1A1 (0.47)
SCHEMBL228021 0.79
SCHEMBL4964823 0.78
SCHEMBL6237757 0.77
SCHEMBL792423 0.77
SCHEMBL12082127 0.77 NPC1 (0.43)
SCHEMBL3061834 0.76
SCHEMBL228277 0.75 ALDH1A1 (0.43)
SCHEMBL17358807 0.75 LMNA (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME KULEON LLC (US) 2026-04-02 US disclosed
US-20250340513-A1 NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS KULEON LLC (US) 2025-11-06 US disclosed
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same Kuleon, LLC (US) 2025-10-14 US disclosed
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME KULEON LLC (US) 2025-09-11 US disclosed
US-12344582-B2 Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression Kuleon, LLC (US) 2025-07-01 US disclosed
US-12275701-B2 Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators Kuleon, LLC (US) 2025-04-15 US disclosed
US-20250091991-A1 MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION Kuleon, LLC (US) 2025-03-20 US disclosed
US-12187678-B2 Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators Kuleon, LLC (US) 2025-01-07 US disclosed
US-20240343690-A1 Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor Modulators KULEON LLC (US) 2024-10-17 US disclosed
CN-118599033-A Chelate resin and preparation method and application thereof 上海稀固科技有限公司 2024-09-06 CN disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 EP disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
CN-1622934-A Short-acting sedative hypnotic agents for anesthesia and sedation THERAVANCE INC (US) 2005-06-01 CN disclosed
US-20050113364-A1 Short-acting sedative hypnotic agents for anesthesia and sedation THERAVANCE BIOPHARMA R&D IP, LLC 2005-05-26 US disclosed
US-6887866-B2 Short-acting sedative hypnotic agents for anesthesia and sedation THERAVANCE, INC. (US) 2005-05-03 US disclosed
EP-1509492-A2 SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION Theravance, Inc. (US) 2005-03-02 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed
WO-2004037750-A2 SHORT-ACTING SEDATIVE HYPNOTIC AGENTS FOR ANESTHESIA AND SEDATION THERAVANCE, INC. (US) 2004-05-06 WO disclosed
US-20030153554-A1 Short-acting sedative hypnotic agents for anesthesia and sedation THERAVANCE BIOPHARMA R&D IP, LLC 2003-08-14 US disclosed